Q2 2026 mARKet Update Summary

Moderated by Portfolio Manager Dan White, CFA, ARK's July Market Update webinar opened with a macroeconomic overview by Cathie Wood, ARK's Chief Executive Officer and Chief Investment Officer. The broader discussion then turned to the prospective Tesla-SpaceX merger and the robotaxi opportunity, the broader commercial space ecosystem and AI's energy needs, the competitive landscape among the latest frontier AI model releases, bitcoin's on-chain bottoming signals, and the long-term investment case for PacBio and the genomics platform. View the full webinar [HERE]

ARK’s research has a very favorable outlook for shares of Tesla. Why would Tesla shareholders approve a merger with SpaceX that values Tesla at anything less than that?

Tasha Keeney, CFA, Director of Research, Autonomous Technology & Robotics / Director of Investment Analysis, explained that ARK expects the robotaxi opportunity to account for the majority of Tesla's enterprise value within five years, and that a merger could still make sense for shareholders for several reasons. SpaceX may need to pay a premium for Tesla given Elon Musk's comparatively smaller controlling stake in Tesla today, and a combined entity would ease the strain on management bandwidth as Musk's team pushes the frontier across multiple industries simultaneously. Tasha noted that the two companies are also increasingly interdependent: Tesla's robotaxi business could generate recurring cash flow that SpaceX could redirect toward its AI ambitions, xAI's models could power the planning and orchestration layer for Optimus, and the Terafab in-house chip initiative would help both companies work around ongoing compute constraints. ARK's initial modeling suggests that factoring in this cross-company cash flow could add incremental value for investors.

Which companies outside of SpaceX are most promising in the commercial space sector?

Daniel Maguire, ACA, Research Analyst, Autonomous Technology & Robotics, framed the opportunity across launch providers and in-space systems. SpaceX holds roughly a ten-year lead in reusability, but its S-1 has signaled that the workhorse Falcon 9 rocket is likely to retire over the next several years, opening a gap for other providers. Daniel highlighted Rocket Lab as the most active launch provider outside of SpaceX and China, noting its partially reusable Neutron rocket and its agreement to acquire satellite communications company Iridium, a deal that positions Rocket Lab as a vertically integrated company spanning launch, manufacturing, and communications. He also pointed to private players such as Blue Origin and Stoke Space pursuing full reusability, Intuitive Machines for lunar infrastructure amid growing national-security urgency, Amazon's Project Leo satellite constellation, and ARK Venture Fund holding Portal Space Systems, which is developing maneuverability solutions to keep satellites from colliding as orbital traffic increases. On the energy side, he flagged nuclear-adjacent names held across ARK funds and the ARK Venture Fund—Oklo, X-Energy, BWXT, Cameco, and Radiant—as exposed to potential fission power for lunar operations.

Can you talk about the energy needs for AI, including the space play?

Daniel Maguire identified power access as the single biggest bottleneck facing AI infrastructure today, a constraint fueling growth at companies like CoreWeave and Crusoe as well as hyperscalers such as Amazon and Google that have the capital and expertise to secure it. ARK estimates that AI infrastructure will require roughly 200 to 400 gigawatts of power in total through 2031, a figure Daniel noted is achievable terrestrially given that China alone added ~500 gigawatts of capacity in a single year. Space nonetheless offers a meaningful release valve: SpaceX's S-1 disclosed plans to launch AI-focused satellites in 2028, targeting 100 gigawatts of AI compute per year from Earth-based operations—equivalent to the entire US nuclear industry, which supplies about 20% of domestic electricity—and eventually up to one terawatt per year from the moon via a lunar mass driver. Starship, and its recently launched version three, remains the critical enabler to watch as SpaceX works toward commercializing AI satellites. On the nuclear side supporting this build-out, Daniel offered a quick reference: Cameco supplies uranium, BWXT supplies reactor components, Oklo and X-Energy are advancing small modular reactors at roughly one-third the size of traditional plants, and Radiant is developing micro-reactors at roughly one-thousandth that scale, a form factor of particular interest for NASA's lunar plans.

What’s your estimate of Optimus rollout to the public, or select corporations?

Tasha Keeney said Tesla has indicated that it could begin selling Optimus externally within roughly the next year, with ARK's published research anticipating that Optimus could reach human-competitive task proficiency by 2028. She expects initial sales to favor other businesses first, given their lower price sensitivity and potential for larger fleet orders, before expanding into home use. ARK sizes the total humanoid robot opportunity at approximately $26 trillion, split evenly between manufacturing and home robotics, with home adoption expected to follow manufacturing's earlier path to scale.

In the world of frontier AI companies, there were two model releases this week. Can you please give us an update on the latest releases and how they stack up competitively?

Jozef Soja, Research Analyst, AI & Cloud, noted that OpenAI released GPT-5.6 and xAI released Grok 4.5 in the same week, with both representing meaningful leaps in raw performance. As enterprises grow more focused on total AI spend, Jozef said the real headline is efficiency: both releases are considerably less expensive to run than prior generations and comparable competing models, in some cases two to three times less expensive for a given task. The flagship GPT-5.6 Soul variant pairs those savings with output quality comparable to costlier frontier models, while Grok 4.5 and the smallest GPT-5.6 tier offer even steeper cost reductions for tasks that do not require top-tier intelligence—a segment of the market Jozef sees maturing quickly. He expects these more efficient offerings to gain significant traction as real-world production use validates published benchmarks and as the applications they power spread more broadly across enterprises.

Please provide your updated thoughts on bitcoin. Is it close to bottoming out? What do you see for the rest of the year?

David Puell, Research Trading Analyst/Associate Portfolio Manager, Digital Assets, pointed to several on-chain markers historically associated with market bottoms, including the share of bitcoin supply held at a loss exceeding the share held at a profit, a signal of capitulation. Long-term holder supply coins held for more than 155 days reached new all-time highs during the second quarter of 2026, and derivatives markets, particularly on Binance, showed low contagion, consistent with a healthier, less exuberant market. David also noted that concerns tied to quantum-computing research appear largely priced in following earlier sentiment reactions. Strategy's preferred "Stretch" product traded under stress during the quarter, falling to roughly $75 before recovering to around $85 alongside bitcoin's price, a pattern David described as consistent with ongoing accumulation rather than renewed local panic.

Why is PacBio not being valued by the market and the clinics industry?

Ovid Amadi, PhD, Multiomics Portfolio Manager and Director of Research, explained that PacBio's that long-read sequencing technology reads much larger stretches of DNA at once—roughly 30,000 base pairs, versus about 150 for the short-read sequencing that dominates research and clinical use today—making it far more capable of detecting structural and copy-number variants that short-read methods can miss. Ovid attributed the market's skepticism to two factors: near-term revenue softness tied to headwinds in the academic and research end-markets where PacBio still generates a large share of revenue, and the high switching costs facing large clinical labs already validated on short-read platforms. Even so, he noted that clinical sequencing is shifting from whole-exome to whole-genome testing, a step toward the broader sequencing that long-read technology enables, and that PacBio's newly launched Spark Next Chemistry brings its cost per genome close to parity with Illumina, a development Ovid expects to support demand elasticity in both research and clinical settings.

Cathie Wood added that ARK inherited this position and has held it for years on the belief that, while it remains a small allocation across the two portfolios that hold it, it carries an outsized call option on the convergence of AI and sequencing technologies.

ARKG has had a good run year-to-date (YTD) and over the last year, do you think this will continue?

Ovid Amadi said ARK views AI's impact on healthcare as among the most profound applications of the technology, with expanding data generation from tools like next-generation sequencing supporting earlier, more accurate diagnosis and increasingly personalized therapies. He pointed to a flywheel forming across life-science tools, diagnostics, and precision therapeutics companies, citing Twist Bioscience's newer AI-enabled drug discovery business—in which pharmaceutical, biotech, and AI customers commission Twist to synthesize and characterize DNA and proteins for their own model development—as an early example of a nascent business line built on that convergence. On the therapeutics side, Ovid noted that CRISPR Therapeutics' gene-editing treatment for sickle cell disease and beta-thalassemia continues to ramp following a recent pediatric approval, with several additional therapies expected to reach market over the next six to twelve months, including Intellia's CRISPR-based treatment for hereditary angioedema, which recently reported positive Phase 3 data and is moving through U.S. Food and Drug Administration (FDA) review. He added that in-vivo gene editing is expected to generate further clinical data in the second half of the year as it expands into larger cardiovascular indications.

Cathie Wood highlighted growing interest from Anthropic and OpenAI in healthcare data, pointing to the 10x Genomics–Anthropic collaboration as an example, and reiterated that the reopening of merger-and-acquisition activity following an Federal Trade Commission (FTC) environment that had constrained dealmaking for several years has created strategic price discovery as biopharma companies facing an estimated ~$300 billion in revenue at risk from patent expirations over the next five years look to fill that gap through Mergers and acquisitions (M&A).

Conclusion:

The Q2 2026 webinar reinforced a theme that has run through much of ARK's thinking this year: convergence is accelerating across nearly every innovation platform we track. Space and AI infrastructure are becoming inseparable as launch costs fall and power constraints push compute into orbit and eventually toward the moon; frontier AI labs are competing as much on efficiency as on raw capability; bitcoin's on-chain data points to accumulation rather than panic even as headline volatility persists; and genomics, diagnostics, and AI are compounding into a single flywheel reshaping drug discovery and disease treatment. At ARK, we remain focused on the view that today's market, much like the 1980s and 1990s, is climbing a wall of worry while being carried higher by supportive policy, deregulation, and a technology revolution still in its early innings.

Make sure to check out our In The Know video series for deeper insights.

Important Information

Investors should carefully consider the investment objectives and risks as well as charges and expenses of an ARK Fund before investing. This and other information are contained in the ARK Funds’ prospectuses and summary prospectuses, which may be obtained by clicking here. The prospectus and summary prospectus should be read carefully before investing.  

An investment in an ARK Fund is subject to risks and you can lose money on your investment in an ARK Fund. There can be no assurance that the ARK Funds will achieve their investment objectives. The ARK Funds’ portfolios are more volatile than broad market averages. The ARK Funds also have specific risks, which are described in their respective prospectuses.  

The ARK DIET Buffer ETFs have characteristics unlike traditional investment products and are not suitable for all investors. 

The information provided in this material is for informational purposes only and should not be used as the basis for any investment decision and is subject to change without notice. It does not constitute, either explicitly or implicitly, any provision of services or products by ARK, and investors should determine for themselves whether a particular investment management service is suitable for their investment needs. All statements made regarding companies or securities are strictly beliefs and points of view held by ARK and are not endorsements by ARK of any company or security or recommendations by ARK to buy, sell or hold any security. Historical results are not indications of future results.  

Certain of the statements contained in this material may be statements of future expectations and other forward-looking statements that are based on ARK's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. ARK assumes no obligation to update any forward-looking information. ARK and its clients as well as its related persons may (but do not necessarily) have financial interests in securities or issuers that are discussed. Certain information was obtained from sources that ARK believes to be reliable; however, ARK does not guarantee the accuracy or completeness of any information obtained from any third party. 

Digital assets, often referred to as cryptocurrencies, such as bitcoin and ether are relatively new investments, which have unique and substantial risks and which may be more volatile than other types of investments. ARK strongly encourages any investor considering an investment in any digital asset to consult with a financial professional before investing. All statements made regarding digital assets are strictly beliefs and points of view held by ARK and are not recommendations by ARK to buy, sell or hold any digital asset. Historical results are not indications of future results. 

 To view the top ten holdings for ARKK click here. 

To view the top ten holdings for ARKQ click here. 

To view the top ten holdings for ARKW click here. 

To view the top ten holdings for ARKG click here. 

To view the top ten holdings for ARKF click here. 

To view the top ten holdings for ARKX click here. 

To view the top ten holdings for ARKVX click here. 

Holdings are subject to change 

Foreside Fund Services, LLC, distributor.